SCHEMBL23833458

SCHEMBL23833458

COc1ncc(NC(=O)c2cccc(-c3noc(C)n3)c2)cc1S(=O)(=O)Nc1c(C)cccc1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.44
TP53 P04637 3/20 0.42
LMNA P02545 3/20 0.42
KDM4E B2RXH2 3/20 0.41
NPC1 O15118 3/20 0.41
HTT P42858 3/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
HSD17B10 Q99714 3/20 0.41
AURKA O14965 1/20 0.41
AURKB Q96GD4 1/20 0.41
ALDH1A1 P00352 3/20 0.41
TSHR P16473 2/20 0.41
USP2 O75604 1/20 0.41
GAA P10253 2/20 0.40
POLB P06746 1/20 0.40
KIFC1 Q9BW19 2/20 0.40
KEAP1 Q14145 1/20 0.40
NFE2L2 Q16236 1/20 0.40
HTR1D P28221 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25758295 0.86 MAPT (0.52) MAPTTP53LMNAKDM4EHTT
SCHEMBL23840584 0.84 BLK (0.47) MAPTMEN1KMT2AALDH1A1TSHR
SCHEMBL23833422 0.82 CBLB (0.42) MEN1KMT2AAURKBKEAP1NFE2L2
SCHEMBL25483827 0.82 KAT6A (0.45) MAPTLMNAKDM4EMEN1KMT2A
SCHEMBL23840513 0.81 TSHR (0.48) MAPTLMNAKDM4ENPC1MEN1
SCHEMBL30151027 0.81 SMN1; SMN2 (0.45) MAPTKMT2AALDH1A1TSHRSMN1; SMN2
SCHEMBL23833412 0.81 SMN1; SMN2 (0.45) MAPTKMT2AALDH1A1TSHRSMN1; SMN2
SCHEMBL23840626 0.81 LCK (0.53) MAPTHTTMEN1KMT2AGAA
SCHEMBL23840327 0.81 HCRTR2 (0.47) MAPTLMNAKDM4EHTTMEN1
SCHEMBL23840614 0.81 MEN1 (0.43) MAPTLMNAKDM4EHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
EP-4121030-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF Amathus Therapeutics, Inc. (US) 2023-01-25 EP disclosed
WO-2021188907-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, PPM1D MAPT 66/4885TP53 20/4885LMNA 3370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.